Core Viewpoint - The company announced a provision for impairment losses totaling 13,395.59 million yuan for the year 2025, reflecting a significant impact on its financial performance [1][7]. Summary by Sections Impairment Provision Overview - The company conducted an assessment of expected credit losses and impairment tests on its assets, resulting in a total impairment loss provision of 13,395.59 million yuan [1]. Accounts Receivable and Other Receivables - The company recognized an impairment loss of 789.41 million yuan for accounts receivable and 802.75 million yuan for other receivables, totaling 1,592.16 million yuan for 2025 [2]. Inventory - The company reported an impairment loss of 8,916.87 million yuan for inventory, calculated based on the lower of cost and net realizable value [4]. Fixed Assets and Intangible Assets - The impairment loss for fixed and intangible assets amounted to 2,886.56 million yuan, determined by assessing the recoverable amount of these assets [6]. Impact of Impairment Provision - The total impairment losses of 13,395.59 million yuan will reduce the company's consolidated profit for the year 2025 by the same amount [7]. Financial Performance for 2025 - The company achieved a revenue of 936,306.27 million yuan, a decrease of 14.40% year-on-year, and a net profit attributable to shareholders of 94,437.98 million yuan, down 12.85% from the previous year [21]. - The net profit excluding non-recurring gains and losses was 85,178.06 million yuan, reflecting an 18.36% decline compared to the previous year [21]. - The overall gross margin decreased by 6.91 percentage points due to price fluctuations and competitive pressures in the pharmaceutical market [21]. Non-Recurring Gains and Losses - The company experienced an increase in non-recurring gains, contributing an additional 5,226.10 million yuan, although the net profit excluding these gains still showed a significant decline [22].